Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

Pituitary adenomas are common intracranial tumors that are mainly considered as benign.
Rarely, these tumors can exhibit an aggressive behavior, characterized by gross invasion of …

Substantial advances have been made recently in the pathobiology of pituitary tumors.
Similar to many other endocrine tumors, over the last few years we have recognized the role …

Context/Objective: Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas
respond poorly to conventional therapy and cytotoxic drugs. Temozolomide (TMZ) is an oral …

Pituitary carcinomas are rare, accounting for about 0· 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

Pituitary adenomas (PAs) can be classified as non-secreting adenomas, somatotroph
adenomas, corticotroph adenomas, lactotroph adenomas, and thyrotroph adenomas …

Human pituitary adenomas are the most common intracranial neoplasms. Approximately 5%
of them are familial adenomas. Patients with familial tumors carry germline mutations in …

Context: Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic
agent for malignant gliomas. Recently, TMZ has been documented to be effective against …

Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until
identification of metastases. Optimal management and survival outcomes for both are not …